Industry Partner News: Catabasis Completes Phase 3 PolarisDMD Trial Enrollment

Catabasis Pharmaceuticals, Inc. shares a Special Edition Newsletter announcing that the Phase 3 PolarisDMD trial for edasalonexent in Duchenne muscular dystrophy has completed enrollment and exceeded the target enrollment. Read the newsletter here.

“We are thrilled to reach this important milestone. The interest and feedback from families and trial sites has been overwhelmingly positive. At a time when there are multiple trials for Duchenne, we are very pleased that physicians and families chose the Phase 3 PolarisDMD trial for edasalonexent,” said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis. “Edasalonexent has the potential to be a foundational therapy, providing benefit to boys, regardless of their underlying mutation, with the potential to benefit muscle function, as well as cardiac function and bone health. We look forward to completing the trial next year and are working diligently toward the goal of making edasalonexent available to patients.”

To read the full press release regarding the announcement, please click here.